Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a heart drug shield blood vessels from reperfusion damage?

NCT ID NCT07192744

Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether rotigaptide, a drug that improves cell communication, can protect blood vessel function after a temporary blockage of blood flow (ischemia-reperfusion injury). Twelve healthy men received the drug or a placebo while their forearm blood flow was measured. The goal was to see if rotigaptide prevents the blood vessel damage that often occurs when blood flow is restored.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rotigaptide (ZP-123)
What this could lead to
If it works, this could point toward a treatment to protect blood vessels from damage after a heart attack or stroke.
What could go wrong
This is a very small, early study in healthy men, not patients. The results may not apply to real-world disease or lead to a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Sep 2008

Finished

Dec 2009

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * healthy males between 18-65 years of ages, non-smokers. Exclusion Criteria: * Any concurrent illness or chronic medical condition. Concurrent use of vasoactive medication. Smoking history.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischaemic heart diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischaemic heart diseases

Contacts and locations

Locations

  • University of Edinburgh, 49 Little France Crescent

    Edinburgh, EH16 4SB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.